appConfigEntityId

bodyType

customContents

entityId

entityUuid

isVideo

articlePageQuery

article

articleSchemaContent

content

hooksArticlePageAdvertisementConfigArticle

hooksArticlePageFloatingButtonConfigArticle

appConfig

filter

json

liveArticle

Julie Zhang

China’s Innovent Biologics has signed a global collaboration with pharmaceutical giant Pfizer worth up to US$10.5 billion to jointly develop 12 cancer treatment programmes.
The Hong Kong-listed drug maker said it would receive an upfront payment of US$650 million from Pfizer, and it is eligible for up to US$9.85 billion tied to development, regulatory and commercial milestone payments, according to an exchange filing on Friday.
Innovent, which is based in Suzhou in China’s eastern Jiangsu province, will also receive double-digit royalties for each product that gains approval.
The deal covers a portfolio of 12 oncology programmes, comprising eight early-stage assets originated by Innovent and four discovery programmes proposed by Pfizer.
Innovent will lead phase one clinical trials for all 12 programmes before Pfizer leads their global development.
Under four of the programmes, the companies will jointly develop and co-commercialise selected assets in the United States and Europe, while Innovent retains all rights in China.
Pfizer will receive an exclusive licence outside China for another four programmes, and for the remaining four, Pfizer will take on an exclusive global licence.

Innovent’s shares rose 11.36 per cent to HK$83.35 apiece on Friday, outpacing Hong Kong’s benchmark Hang Seng Index.
“The company views this collaboration as another milestone towards achieving global capabilities,” Michael Yu, Innovent Biologics’ chairman and executive director said in the filing. “By leveraging both companies’ complementary resources, [Innovent] can develop its early-stage oncology pipeline with greater speed and impact to help bring innovative therapies to patients more efficiently worldwide.”
“Co-developing and co-commercializing key programmes in the US and Europe expand Innovent’s global reach,” he added.
The tie-up follows Innovent’s US$11.4 billion partnership with Japan’s Takeda Pharmaceutical, announced in October, which gave Takeda rights to develop and commercialise a separate group of oncology assets outside China.
Innovent is the first Chinese company cleared to sell weight loss drugs, and last year reported its first full-year profit since going public in 2018. It posted a net profit of 813.6 million yuan in 2025, compared with a loss of 94.63 million yuan in 2024.
For the first quarter of 2026, its total product revenue amounted to over 3.8 billion yuan, representing a year-on-year growth of over 50 per cent, the company said.


The Innovent-Pfizer deal is the latest example in the transformation in China’s pharmaceutical industry. Cross-border out-licensing by Chinese firms hit US$60 billion in the first quarter of 2026 alone, according to the National Medical Products Administration, almost half of the total out-licensing agreements signed in 2025, which amounted to US$135.7 billion.
The surge is supported by the Chinese government’s policies, as the country’s drug regulator accelerates clinical trial approvals to bring home-grown, innovative drugs to market faster.
China’s regulator has cleared 19 pharmaceuticals so far this year, 15 from domestic companies, according to the regulator’s website as of May 21.
The country now accounts for a larger share of newly launched clinical trials than Europe, and is closing the gap with the United States in the number of new global drug approvals, according to a report published by Dutch financial services group ING on Wednesday.


Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts

Alibaba open-sources medical AI model that can detect cancer and nearly 150 conditions

How China plans to ‘firmly rank at the global forefront’ with 25% of first-in-class drugs

ByteDance spin-off Anew Labs raises US$290m as AI drug developers enjoy fundraising boom

Biomedicine: Companies

China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials

A researcher uses a microscope in a cancer research laboratory. Photo: Shutterstock

A man walks past the logo of the multinational pharmaceutical corporation Pfizer in Berlin. Photo: dpa

China’s drug regulator clears wave of home-grown innovative medicines amid biotech boom

Chinese biotech firms struck a record US$60 billion in cross-border licensing deals in the first quarter of 2026. Photo: Getty Images

Biotech companies, including Fosun Pharma, are ramping up R&D spending. Photo: Shutterstock

Insilico teams up with US firm to build AI models predicting disease decades ahead

The global longevity market, fuelled by an ageing population and rising consumption demand, is currently valued at US$5.3 trillion, according to a UBS report. Photo: Shutterstock

Insilico CEO Alex Zhavoronkov frames the tie-up as the world’s two leading companies in the AI and longevity fields joining forces. Photo: Handout

China’s Hengrui seals US$15.2 billion deal with US pharmaceutical giant BMS

A worker checks a feeding tray at the Hengrui Biomedical Industrial Park in Lianyungang, east China’s Jiangsu province. Photo: Getty Images

BMS will pay Hengrui up to US$950 million in near-term consideration, including an upfront payment of US$600 million. Photo: Handout

Why Hong Kong scientists think GLP-1 weight-loss drugs can help stroke patients

The research is the world’s first phase two clinical trial on the use of GLP-1 for stroke treatment. Photo: Getty Images

(From left) Dr Owen Ko Ho, Professor Thomas Leung and Dr Bonaventure Ip present their findings at a press conference on Thursday. Photo: Sam Tsang

Hong Kong-listed biotech firm uses AI to produce nano-rockets to deliver life-saving drugs

METiS TechBio debuts on Hong Kong stock market and raises HK$2.11 billion (US$269.5 million) from the sale of 201.23 million shares at HK$10.50 each. Photo: Jelly Tse

Business

China Business

Companies

News

China Future Tech

Biomedicine

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer


The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.


China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials

.css-1c6uqr6{color:inherit;font-weight:inherit;font-size:inherit;font-family:inherit;line-height:inherit;overflow-wrap:break-word;}The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer